Since tocilizumab, an antibody against the IL-6 receptor, is one of the most effective drugs for patients with severe COVID-19, we also demonstrated that the levels of both secreted and dimeric intracellular IL-6 were increased in response to both RBD and H2O2 and decreased by CO2 (Fig. 4d–f). The gene discussed is IL6; the disease is COVID-19.